Price target
70.370.000.00%
The 25 analysts offering 1 year price forecasts for 1CG have a max estimate of — and a min estimate of —.
Analyst rating
Based on 31 analysts giving stock ratings to 1CG in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
1CG EPS for the last quarter is −0.86 CHF despite the estimation of −1.17 CHF. In the next quarter EPS is expected to reach −1.10 CHF. Track more of CRISPR THERAPEUTIC financials and stay on top of what is up with the company.
In the next quarter CRISPR THERAPEUTIC revenue is expected to reach 7.92 M CHF. Check out CRISPR THERAPEUTIC revenue and earnings and make informed decisions.
According to analysts, 1CG price target is 70.37 CHF with a max estimate of 174.52 CHF and a min estimate of 26.31 CHF. Check if this forecast comes true in a year, meanwhile watch CRISPR THERAPEUTIC stock price chart and keep track of the current situation with 1CG news and stock market news.
We've gathered opinions of 31 analysts rating 1CG stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.